SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. engages in the integrated hardware and software infrastructure of the future across space, connectivity, and AI. at core, are builders. The firm design, manufacture, launch, and operate products and services built on cutting-edge technologies, including the world’s most advanced rockets and spacecraft. It provides satellite communication services. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is generating massive market buzz following its high-profile public debut, with investors deeply divided over whether the company's multi-trillion dollar valuation reflects revolutionary long-term potential or unsustainable hype. The community is actively debating the stock's future, as traders closely monitor high volatility and look ahead to upcoming options trading, index inclusion, and the potential impact of insider lock-up expirations.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is trending following a Bloomberg report that the streaming company is exploring a potential sale, with discussions reportedly underway with at least one major U.S. media entity. The community is actively debating the credibility of these buyout rumors and the company's long-term strategic value, leading to significant volatility as traders analyze the potential for a premium acquisition against the backdrop of an increasingly competitive streaming landscape.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean Ltd. is currently trending as investors weigh strong backlog growth and improved operational efficiency against geopolitical uncertainty in the Strait of Hormuz. The community is actively debating whether the stock's recent performance is tethered more to daily fluctuations in oil prices or the long-term potential of its merger with Valaris and ongoing debt reduction efforts.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corporation is currently in focus as investors analyze the company's first commercial revenue data following the FDA approval of YARTEMLEA. The community is actively debating the potential impact of competitive threats at the EHA conference, upcoming regulatory milestones in Europe, and the significance of the permanent J-code implementation for long-term commercial momentum.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending as community excitement peaks following a major expansion of its Arizona manufacturing footprint, which positions the company to become a critical hub in the U.S. AI chip supply chain. Investors are actively discussing the stock's role as a key 'pick-and-shovel' play for the semiconductor industry, with many highlighting its strategic partnerships and potential for sustained growth as a critical packaging partner for leading AI chip designers.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as investors debate its long-term utility against a prolonged downtrend, with the community closely tracking upcoming legislative developments like the CLARITY Act for potential catalysts. While some holders continue to accumulate on the dip citing the project's compliance focus and infrastructure potential, others are increasingly vocal about their frustration regarding lack of communication and poor price performance.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Trulieve is currently trending as investors debate the impact of its recent NYSE uplisting, which has been met with significant volatility and lower-than-expected volume. Community discussion is focused on the potential for institutional accumulation, the unwinding of complex swaps, and skepticism regarding whether this transition will effectively bridge the gap between retail sentiment and broader market participation.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

SPRY is surging as investors react to a significant regulatory delay for its primary competitor, Aquestive Therapeutics, effectively extending SPRY's lead as the only approved needle-free epinephrine treatment. The community is actively discussing a potential short squeeze, fueled by high short interest and institutional accumulation, as the company scales its global market presence.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is experiencing heightened interest as investors weigh record-high Nasdaq levels against volatile geopolitical developments, including U.S.-Iran tensions. The community is actively debating the sustainability of the AI-driven tech rally and the risks associated with holding triple-leveraged instruments in an environment characterized by inflation concerns and potential policy shifts.

GitLab, Inc. engages in the intelligent development, security, and operations (DevSecOps) platform for software innovation. It enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab is facing a sharp selloff following a weaker-than-expected full-year revenue outlook, even after beating quarterly earnings estimates. The market is expressing significant frustration with the stock's performance, as investors debate whether the $400 million share buyback provides a firm floor or if the company's valuation faces further compression in the current AI-focused market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of -6.88% and -98.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Innoviva (INVA) Tops Q1 Earnings Estimates

Innoviva (INVA) delivered earnings and revenue surprises of +3.53% and -1.83%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?

The mean of analysts' price targets for Celldex (CLDX) points to a 76.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Pictet Asset Management Holding SA Reduces Holdings in Celldex Therapeutics, Inc. $CLDX

Pictet Asset Management Holding SA reduced its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 20.1% during the fourth quarter, according to the company in its most...

Celldex Therapeutics (NASDAQ:CLDX) Shares Pass Above 200 Day Moving Average - What's Next?

Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200-Day Moving Average - Here's Why...

Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up  Following Analyst Upgrade

Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up Following Analyst Upgrade...

Celldex Therapeutics (NASDAQ:CLDX) Upgraded at Barclays

Barclays raised shares of Celldex Therapeutics from an "underweight" rating to an "overweight" rating and set a $45.00 price target for the company in a report on Monday...

Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month High - Here's What Happened

Celldex Therapeutics (NASDAQ:CLDX) Sets New 52-Week High - Time to Buy...

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have received a consensus rating of "Moderate Buy" from the twelve analysts that are currently covering the firm, Marketbeat.com...

Tudor Investment Corp ET AL Makes New $818,000 Investment in Celldex Therapeutics, Inc. $CLDX

Tudor Investment Corp ET AL purchased a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 31,618 shares of the biopharmaceutical company's stock...

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

CLDXCelldex Therapeutics Inc.

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CLDX News